Tijdschrift voor kindergeneeskunde

, Volume 68, Issue 3, pp 135–138 | Cite as

Langwerkende β 2-mimetica bij de behandeling van astma bij kinderen

  • A. A. P. H. Vaessen-Verberne


Two long-acting inhaled β 2-agonists are currently available for the treatment of childhood asthma. Compared to short-acting b 2-agonists, formoterol and salmeterol have a longer duration of action, which is at least 12 hours for the bronchodilating effect. Although during continuous treatment tolerance will develop, especially for the protecting effects, residual protection remains even during long-term treatment. Formoterol and salmeterol should only be used in combination with inhaled corticosteroids in children with moderate to severe asthma, who do have persisting symptoms despite beclomethason or budesonide 400-800 μg daily or fluticason 250-500 μg daily. For every single patient it should be decided which is more appropriate: the addition of a long-acting β 2-agonist or increasing the dose of inhaled corticosteroid.


Twee langwerkende inhalatie-β 2-sympaticomimetica, formoterol en salmeterol, zijn de laatste jaren beschikbaar gekomen voor de behandeling van astma bij kinderen. Ten opzichte van kortwerkende β 2-sympaticomimetica onderscheiden zij zich door hun lange werkingsduur; voor wat het bronchusverwijdende effect is dit tenminste 12 uur. Hoewel tijdens continu gebruik een zekere tolerantie optreedt, blijven significante beschermende effecten ook bij langdurig gebruik bestaan. Deze middelen kunnen in combinatie met inhalatiesteroïden worden gebruikt bij kinderen met matig ernstig tot ernstig astma. Bij persisteren van astmaklachten ondanks onderhoudsbehandeling met inhalatiesteroïden in een dosering van 400-800 μg beclometason of budesonide of 250-500 μg fluticason per dag, dient gekozen te worden voor hetzij verhoging van de dosering inhalatiesteroïden hetzij de toevoeging van een langwerkend β 2-sympaticomimeticum.


  1. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-3; case-control study. Lancet 1989;i:917-22.Google Scholar
  2. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.PubMedCrossRefGoogle Scholar
  3. Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Resp J 1994;7:1602-9.CrossRefGoogle Scholar
  4. Sears MR, Taylor DR, Pring CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.CrossRefPubMedGoogle Scholar
  5. Schayck CP van, Dompeling E, Herwaarden CLA van, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A rondomized controlled study. Br Med J 1991;303:1426-31.CrossRefGoogle Scholar
  6. Schayck CP van, Dompeling E, Herwaarden CLA van, et al. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis; four-year follow-up randomized controlled study. Br J Gen Pract 1995;45:239-44.PubMedGoogle Scholar
  7. Town GI, O'Donnell TV, Purdie G. Bronchial responsiveness during regular fenoterol therapy: four months prospective study. N Z Med J 1991;104:3-5.PubMedGoogle Scholar
  8. Anderson GP, Linden A, Rabe KF. Why are long-acting beta2-adrenoceptor agonists long-acting? Eur Respir J 1994;7: 569-78.CrossRefPubMedGoogle Scholar
  9. Graff-Lonnevig V, Browaldh L. Twelve hours bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol. Clin Exp Allergy 1990;20:429-32.CrossRefPubMedGoogle Scholar
  10. Verberne AAPH, Hop WCJ, Bos AB, Kerrebijn KF. Effect of a single dose of inhaled salmeterol on baseline airway calibre and metacholine-induced airway obstruction in asthmatic children. J Allergy Clin Imunol 1993;91:127-34.CrossRefGoogle Scholar
  11. Barbato A, Tomena F, Novella A. The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children. Allergy 1995;50:506-10.CrossRefPubMedGoogle Scholar
  12. Boner AL, Spezia E, Piovesan P. Inhaled formoterol in the prevention of exercise induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994;149:935-9.PubMedGoogle Scholar
  13. De Benedictis FM, Tuteri G, Pazzell P, et al. Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses. Eur Respir J 1996;9:2099-103.CrossRefPubMedGoogle Scholar
  14. Twentyman OP, Finnerty JP, Harrris A, et al. Protection against allergen-induced asthma by salmeterol. Lancet 1990;336:1338-42.CrossRefPubMedGoogle Scholar
  15. Lenney W, Pedersen S, Boner AC, et al. Efficacy and safety for salmeterol in childhood asthma. Eur J Paediatr 1995;154:983-90.CrossRefGoogle Scholar
  16. Langton Hewer S, Hobbs J, French D, Lenney W. Pilgrim's progress; the effect of salmeterol in older children with chronic severe asthma. Respir Med 1995;89:435-40.CrossRefPubMedGoogle Scholar
  17. Verberne AAPH, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-95.PubMedGoogle Scholar
  18. Simons FER. Canadian Beclomethasone dipropionate-salmeterol xinafoate study group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.CrossRefPubMedGoogle Scholar
  19. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.CrossRefPubMedGoogle Scholar
  20. Pauwels R, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.CrossRefPubMedGoogle Scholar
  21. Verberne AAPH, Frost C, Duiverman EJ, et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med 1998;158: 213-9.PubMedGoogle Scholar
  22. Verberne AAPH, Hop WCJ, Creyghton FB, et al. Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. J Allergy Clin Immunol 1996;97:938-46.CrossRefPubMedGoogle Scholar
  23. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88:373-81.CrossRefPubMedGoogle Scholar
  24. Redington AE, Howarth PH. Airway wall remodeling in asthma. Thorax 1997;52:310-2.CrossRefPubMedGoogle Scholar
  25. Hoekstra MO. Consensus van de Nederlandse kinderartsen voor longziekten betreffende de behandeling van chronisch astma bij kinderen. Ned Tijdschr Geneeskd 1997;141:2223-9.PubMedGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum 2000

Authors and Affiliations

  • A. A. P. H. Vaessen-Verberne
    • 1
  1. 1.

Personalised recommendations